Diffuse large B-cell lymphoma trials in China

In China 133 Also abroad 346

133 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.

No phaseTaking people
An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
Where
Beijing, Changchun, Chengdu, Guangzhou, Harbin, Jinan, Langfang, Nanchang, Ningbo, Shanghai, Tianjin, Wenzhou, Wuhan, Xi'an, Yantai, Zhengzhou
Age
18 years and over
People
300 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07200375
Phase 2Not yet taking people in China
Prophylactic Strategies for Mitigating Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma
Where
Beijing
Age
18 years to 80 years
People
87
Run by
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07917624
Phase 2/3Taking people
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Where
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Luoyang, Nanchang, Shanghai, Wuhan, Zhengzhou
Age
18 years and over
People
290 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT05139017 · EU 2022-502646-27-00
Phase 4Taking people
Efficacy and Safety of Polatuzumab Vedotin, Rituximab Combined With Reduced-dose Cyclophosphamide, Doxorubicin and Prednisone Regimen in the Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma: A Multicenter, Single-arm, Prospective Study
Where
Changchun
Age
65 years and over
People
26
Run by
The First Hospital of Jilin University
See details and how to joinNCT07908888
Phase 1Taking people
KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Where
Wuhan
Age
18 years to 65 years
People
18
Run by
TCRx Therapeutics Co.Ltd
See details and how to joinNCT07260812
Phase 3Taking people
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Where
Beijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Hefei, Jinan, Kunming, Linyi, Nanchang, Nanning, Nantong, Shanghai, Taiyuan, Tianjin, Wuhan, Xiamen, Xi’an
Age
18 years and over
People
1,046 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06717347 · EU 2024-515566-13-00
Phase 2Taking people
Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL
Where
Shanghai
Age
70 years and over
People
38
Run by
Shanghai Zhongshan Hospital
See details and how to joinNCT07012980
No phaseTaking people
Prospective ctDNA Testing in Large B-Cell Lymphoma
Where
Beijing
Age
18 years and over
People
100
Run by
Peking University People's Hospital
See details and how to joinNCT07878351
Phase 1Taking people
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Where
Changsha, Chengdu, Guangzhou, Nanjing, Wenzhou
Age
18 years and over
People
453 worldwide
Run by
Pfizer
See details and how to joinNCT03460977 · EU 2023-509179-18-00
Phase 1Taking people
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Where
Zhengzhou
Age
18 years and over
People
180 worldwide
Run by
Ascentage Pharma Group Inc.
See details and how to joinNCT07424833
Phase 3Taking people
A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Where
Beijing
Age
18 years to 75 years
People
282
Run by
Shanghai Junshi Bioscience Co., Ltd.
See details and how to joinNCT07808827
Phase 1/2Taking people
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Where
Beijing, Guangzhou, Shanghai, Tianjin, Wenzhou, Yichang, Zhengzhou
Age
18 years and over
People
689 worldwide
Run by
BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00
Phase 1/2Not yet taking people in China
A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma
Where
Guangzhou, Suzhou
Age
18 years to 75 years
People
204
Run by
Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT07818499
Phase 1Taking people
Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma
Where
Tianjin
Age
18 years to 75 years
People
18
Run by
Shanghai Exuma Biotechnology Ltd.
See details and how to joinNCT06830031
Phase 2Not yet taking people in China
Pirtobrutinib Plus Methotrexate-Based Chemoimmunotherapy for Systemic DLBCL With CNS Involvement
Where
Shanghai
Age
14 years to 80 years
People
24
Run by
Pengpeng Xu
See details and how to joinNCT07812493
Phase 1Taking people
A Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Where
Guangzhou, Shanghai
Age
18 years and over
People
42
Run by
Guangzhou Lupeng Pharmaceutical Company LTD.
See details and how to joinNCT07570017
Phase 1/2Taking people
A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
Where
Hangzhou
Age
18 years to 75 years
People
70
Run by
Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT07788118
No phaseTaking people
Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL
Where
Xiamen
Age
18 years and over
People
30
Run by
The First Affiliated Hospital of Xiamen University
See details and how to joinNCT07778212
Phase 3Taking people
Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Where
Beijing
Age
18 years to 75 years
People
416
Run by
BeBetter Med Inc
See details and how to joinNCT06792253
Phase 2Not yet taking people in China
Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma
Where
Suzhou
Age
18 years and over
People
39
Run by
The First Affiliated Hospital of Soochow University
See details and how to joinNCT07774234
No phaseNot yet taking people in China
R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS Lymphoma
Where
Changzhou, Huai'an, Nanjing, Wuxi, Yixing
Age
18 years to 80 years
People
58
Run by
WEI XU
See details and how to joinNCT07764601
Phase 3Taking people
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Where
Beijing
Age
18 years to 80 years
People
101
Run by
Sinocelltech Ltd.
See details and how to joinNCT07570823
Phase 2Not yet taking people in China
Pirtobrutinib+Pola-R-CHP for Newly Diagnosed Non-GCB DLBCL
Where
Nanjing
Age
18 years to 65 years
People
48
Run by
Changzhou No.2 People's Hospital
See details and how to joinNCT07744724
Phase 2Not yet taking people in China
Pirtobrutinib + R-CHOP for Untreated Non-GCB DLBCL
Where
Nanjing
Age
18 years to 80 years
People
34
Run by
Changzhou No.2 People's Hospital
See details and how to joinNCT07744737
Phase 2Not yet taking people in China
Pirtobrutinib+Sonrotoclax（PS) Regimen in the Treatment of B-Cell Lymphoma
Where
Nanjing
Age
18 years and over
People
40
Run by
Changzhou No.2 People's Hospital
See details and how to joinNCT07744750